Assessment of Potential Drug-Drug Interactions Among Patients With Ovarian Cancer Receiving Olaparib

Ovarian cancer (OC) patients receiving olaparib (OLA) frequently manage multiple comorbidities, leading to high rates of polypharmacy. Given that OLA is metabolized by CYP3A4, the population faces an elevated risk of potential drug-drug interactions (pDDIs), which can compromise treatment efficacy or patient safety. The retrospective study aimed to describe the frequency and severity of potential drug–drug interactions (pDDIs). We retrospectively analyzed 49 OC patients receiving OLA. Patient data were collected to identify pDDIs using a validated drug interaction checker. OLA trough plasma concentrations (Ctrough) were measured using a validated UPLC-MS/MS method. Statistical analysis utilized Spearman's rank correlation and Poisson regression to assess the relationship between the number of drugs and interactions. Within the 49 OC patients, 32 pharmacokinetic pDDIs were identified. There was a significant (p